Source-grounded facts extracted from Disc Medicine, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Disc Medicine, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $63.5 million for the three months ended March 31, 2026.
“On May 5, 2026, Disc Medicine, Inc. announced its financial results for the first quarter ended March 31, 2026 and provided a corporate update.”
Disc Medicine, Inc. announced a restructuring with charges of approximately $2.0 million affecting commercial functions and certain supporting functions (approximately 20%).
“Company expects to complete the implementation of the Restructuring Plan in the second quarter of 2026. The Company expects that it will incur aggregate charges of approximately $2.0 million in connection with the Restructuring Plan, consisting primarily of severance costs, which will be recorded primarily in the first quarter of 2026. The costs that the Company”
Disc Medicine, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $26.9 million.
“Disc Medicine, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update.”
Disc Medicine, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $76.4 million.
“Disc Medicine, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023”
Jonathan Yu changed role as Chief Operating Officer at Disc Medicine, Inc..
“On February 7, 2024 (the "Promotion Date"), the Company announced that Jonathan Yu, the Company's previous Chief Business Officer, was promoted to serve as the Company's Chief Operating Officer.”
Joanne Bryce departed as Chief Financial Officer and Treasurer at Disc Medicine, Inc..
“Ms. Franchi succeeds Joanne Bryce, who, as previously announced by the Company, will depart from her role as Chief Financial Officer and Treasurer, effective as of the Effective Date.”
Jean M. Franchi was appointed as Chief Financial Officer and Treasurer at Disc Medicine, Inc..
“On February 7, 2024, the Company announced the appointment of Jean M. Franchi as Chief Financial Officer and Treasurer, effective February 7, 2024”
Disc Medicine, Inc. amended Open Market Sale Agreement with Jefferies LLC valued at Increase aggregate offering price from $59.7 million to $200.0 million (effective 2023-12-05).
“On December 5, 2023, the Company and Jefferies entered into an amendment to the Agreement (the “Amendment”) to increase the aggregate offering price of the shares of common stock that the Company may offer under the Agreement from $59.7 million to $200.0 million (the “Additional Shares”).”
Disc Medicine, Inc. reported third quarter ended September 30, 2023 results: net income Net loss was $14.1 million.
“• Net Loss: Net loss was $14.1 million for the quarter ended September 30, 2023, as compared to”
Joanne Bryce departed as Chief Financial Officer at Disc Medicine, Inc..
“On October 23, 2023, Disc Medicine, Inc. (the “Company”) announced that Joanne Bryce plans to depart from her position as Chief Financial Officer effective upon the Company identifying her successor.”
Disc Medicine, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $59.7 million (effective 2023-10-10).
“On October 10, 2023, Disc Medicine, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, or directly to Jefferies, acting as principal, shares of the Company’s common stock, par value $0.0001 per share (“common stock”).”
Disc Medicine, Inc. terminated Sales Agreement with Leerink Partners LLC (f/k/a SVB Securities LLC) valued at Termination of Sales Agreement without penalties (effective 2023-09-28).
“On September 20, 2023, the Company delivered written notice to Leerink Partners LLC (f/k/a SVB Securities LLC) ("Leerink") that it was terminating the Sales Agreement dated January 25, 2023 (the "Sales Agreement"), by and between the Company and Leerink, in accordance with its terms, which termination became effective on September 28, 2023.”
Disc Medicine, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $15.9 million for the quarter ended June 30, 2023.
“Disc Medicine, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023 and provided a corporate update.”
Disc Medicine, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, SVB Securities LLC, Stifel, Nicolaus & Company, Incorporated, BMO Capital Markets Corp. valued at $128.2 million net proceeds from public offering of common stock and pre-funded warrants (effective 2023-06-13).
“On June 13, 2023, Disc Medicine, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, SVB Securities LLC, Stifel, Nicolaus & Company, Incorporated, and BMO Capital Markets Corp., as representatives of the several underwriters listed on Schedule I thereto (the “Underwriters”), related to a public offering (the “Offering”) of (i) 2,595,919 shares of common stock of the Company, par value $0.0001 per share (“Common Stock”) at a price to the public of $49.00 per share and (ii) pre-funded warrants to purchase an aggregate of 204,081 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $48.9999 per Pre-Funded Warrant, which represents the per share public offering price for the Common Stock less the $0.0001 per share exercise price for each such Pre-Funded Warrant.”
Disc Medicine, Inc. shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm at the 2023-06-09 meeting.
“Proposal 2 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Abstain 13,678,267 18,084 373,951”
Disc Medicine, Inc. shareholders approved Election of Class II and Class III Director Nominees at the 2023-06-09 meeting.
“Proposal 1 - Election of Class II and Class III Director Nominees The stockholders of the Company elected Georges Gemayel, Ph.D., Mark Chin, MS, MBA, and Liam Ratcliffe, M.D., Ph.D. as Class II directors of the Company, for a two-year term ending at the annual meeting of stockholders to be held in 2025 and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Georges Gemayel, Ph.D. 13,073,343 16,929 980,030 Mark Chin, MS, MBA 13,073,267 17,005 980,030 Liam Ratcliffe, M.D., Ph.D. 13,081,593 8,679 980,030 The stockholders of the Company elected Donald Nicholson, Ph.D., William White, MPP, J.D., and John Quisel, J.D., Ph.D. as Class III directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2026 and until their successors h”
Disc Medicine, Inc. reported financial results for first quarter ending March 31, 2023.
“Disc Medicine, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023”
Jay T. Backstrom, M.D., M.P.H. resigned as member of the Board of Directors at Disc Medicine, Inc..
“On April 18, 2023, Jay T. Backstrom, M.D., M.P.H., a member of the Board of Directors (the “Board) of Disc Medicine, Inc. (the “Company”), notified the Company of his resignation from the Board effective as of the close of business on June 9, 2023.”
Disc Medicine, Inc. reported financial results for the full year ended December 31, 2022.
“On March 31, 2023, Disc Medicine, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2022 and provided a corporate update.”
Disc Medicine, Inc. entered into Purchase Agreement with the investors identified therein valued at approximately $62.5 million (effective 2023-02-13).
“On February 13, 2023, Disc Medicine, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the investors identified therein.”
Disc Medicine, Inc. entered into Sales Agreement with SVB Securities LLC valued at up to $100.0 million (effective 2023-01-25).
“On January 25, 2023, Disc Medicine, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with SVB Securities LLC (“SVB Securities”) pursuant to which the Company may, from time to time in its sole discretion, issue and sell through SVB Securities, acting as sales agent, shares of the Company’s common stock, par value $0.0001 per share (the “Placement Shares”). The issuance and sale, if any, of Placement Shares with an aggregate offering price of up to $100.0 million by the Company under the Agreement will be made pursuant to a prospectus supplement to the Company’s registration statement on Form S-3 (File No. 333-269272), originally filed with the Securities and Exchange Commission (the “SEC”) on January 18, 2023, which became effective on January 24, 2023.”
Disc Medicine, Inc. entered into Exclusive License Agreement with Mabwell Therapeutics, Inc. valued at $10 million dollars (effective 2023-01-19).
“On January 19, 2023, Disc Medicine, Inc. (“Disc”) entered into an exclusive license agreement with Mabwell Therapeutics, Inc. (“Mabwell”) (a wholly-owned subsidiary of Mabwell (Shanghai) Bioscience Co., Ltd), pursuant to which Mabwell granted Disc an exclusive and sublicensable license under certain patent rights, know-how, and materials to develop and commercialize antibody products containing Mabwell’s MWTX-001, MWTX-002, and MWTX-003 antibodies, along with limited variants thereof, in all fields of use, in all territories other than Greater China (Mainland China, Hong Kong, Macau and Taiwan) and Southeast Asia (Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, Philippines, Singapore, Thailand and Vietnam).”
Disc Medicine, Inc.: Filed a certificate of amendment to change the company's name from 'Gemini Therapeutics, Inc.' to 'Disc Medicine, Inc.' (effective 2022-12-29).
“On December 29, 2022, the Company filed a certificate of amendment (the “ Name Change Amendment ”) to the Company’s certificate of incorporation with the Secretary of State of the State of Delaware to change the name of the Company to “Disc Medicine, Inc.” effective as of 5:02 p.m. on December 29, 2022.”
Disc Medicine, Inc.: Approved and filed an amendment to the amended and restated certificate of incorporation to effect a 1-for-10 reverse stock split (effective 2022-12-29).
“At the Special Meeting, the Company’s stockholders approved an amendment to the amended and restated certificate of incorporation of the Company (the “ Stock Amendment ”) to effect the Reverse Stock Split and the Common Stock Reduction. On December 28, 2022, the Company filed the Stock Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split effective as of 5:00 p.m. on December 29, 2022.”
Disc Medicine, Inc. completed an acquisition involving Disc (closed 2022-12-29).
“On December 29, 2022, the Company completed its business combination with Disc in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August 9, 2022”
John Quisel was appointed as Director at Disc Medicine, Inc..
“Donald Nicholson, William White and John Quisel appointed as Class III directors”
William White was appointed as Director at Disc Medicine, Inc..
“Donald Nicholson, William White and John Quisel appointed as Class III directors”
Donald Nicholson was appointed as Executive Chairman at Disc Medicine, Inc..
“Donald Nicholson, Ph.D. was appointed as the executive chairman of the board.”
Liam Ratcliff was appointed as Director at Disc Medicine, Inc..
“Georges Gemayel, Mark Chin and Liam Ratcliff appointed as Class II directors”
Mark Chin was appointed as Director at Disc Medicine, Inc..
“Georges Gemayel, Mark Chin and Liam Ratcliff appointed as Class II directors”
Georges Gemayel was appointed as Director at Disc Medicine, Inc..
“Georges Gemayel, Mark Chin and Liam Ratcliff appointed as Class II directors”
Jay Backstrom was appointed as Director at Disc Medicine, Inc..
“Mona Ashiya, Kevin Bitterman and Jay Backstrom appointed as Class I directors”
Kevin Bitterman was appointed as Director at Disc Medicine, Inc..
“Mona Ashiya, Kevin Bitterman and Jay Backstrom appointed as Class I directors”
Mona Ashiya was appointed as Director at Disc Medicine, Inc..
“Mona Ashiya, Kevin Bitterman and Jay Backstrom appointed as Class I directors”
Jim Tananbaum resigned as Director at Disc Medicine, Inc..
“Carl Gordon, Ph.D., CFA, David Lubner, Tuyen Ong, M.D., MRCOphth., Jason Rhodes and Jim Tananbaum, M.D. resigned from the Company’s board of directors and committees of the board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Jason Rhodes resigned as Director at Disc Medicine, Inc..
“Carl Gordon, Ph.D., CFA, David Lubner, Tuyen Ong, M.D., MRCOphth., Jason Rhodes and Jim Tananbaum, M.D. resigned from the Company’s board of directors and committees of the board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Tuyen Ong resigned as Director at Disc Medicine, Inc..
“Carl Gordon, Ph.D., CFA, David Lubner, Tuyen Ong, M.D., MRCOphth., Jason Rhodes and Jim Tananbaum, M.D. resigned from the Company’s board of directors and committees of the board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
David Lubner resigned as Director at Disc Medicine, Inc..
“Carl Gordon, Ph.D., CFA, David Lubner, Tuyen Ong, M.D., MRCOphth., Jason Rhodes and Jim Tananbaum, M.D. resigned from the Company’s board of directors and committees of the board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Carl Gordon resigned as Director at Disc Medicine, Inc..
“Carl Gordon, Ph.D., CFA, David Lubner, Tuyen Ong, M.D., MRCOphth., Jason Rhodes and Jim Tananbaum, M.D. resigned from the Company’s board of directors and committees of the board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Disc Medicine, Inc. shareholders approved Approval of amendments to the Company’s 2021 Stock Option and Incentive Plan and the Company’s 2021 Employee Stock Purchase Plan to (i) increase the number of shares of common stock reserved for issuance under the Company’s 2021 Stock Option and Incentive Plan to a number of shares representing appr at the 2022-12-28 meeting.
“Proposal No. 4. Approval of amendments to the Company’s 2021 Stock Option and Incentive Plan and the Company’s 2021 Employee Stock Purchase Plan to (i) increase the number of shares of common stock reserved for issuance under the Company’s 2021 Stock Option and Incentive Plan to a number of shares representing approximately 9% of the fully diluted capitalization of the Company, determined as of immediately following the Merger and (ii) increase the number of shares of common stock reserved for issuance under the Company’s 2021 Employee Stock Purchase Plan to a number of shares representing approximately 0.84% of the fully diluted capitalization of the Company, determined as of immediately following the Merger. This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain BROKER NON-VOTES 34,522,687 2,891,507 44,595 2,843,872”
Disc Medicine, Inc. shareholders approved Approval, on a nonbinding, advisory basis, of the compensation that will or may become payable by the Company to its named executive officers in connection with the Merger. at the 2022-12-28 meeting.
“Proposal No. 3. Approval, on a nonbinding, advisory basis, of the compensation that will or may become payable by the Company to its named executive officers in connection with the Merger. This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain BROKER NON-VOTES 32,201,605 5,212,578 44,606 2,843,872”
Disc Medicine, Inc. shareholders approved Approval of an amendment to the amended and restated certificate of incorporation of the Company to (a) effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio of one new share of the Company’s common stock for every ten shares of outstanding common stock of the at the 2022-12-28 meeting.
“Proposal No. 2. Approval of an amendment to the amended and restated certificate of incorporation of the Company to (a) effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio of one new share of the Company’s common stock for every ten shares of outstanding common stock of the Company, and (b) implement a reduction in the number of authorized shares of the Company’s common stock to 100,000,000. This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain BROKER NON-VOTES 39,833,612 421,352 47,697 -”
Disc Medicine, Inc. shareholders approved Approval of (i) the issuance of shares of common stock of the Company, which will represent more than 20% of the shares of the Company’s common stock outstanding immediately prior to the Merger, to stockholders of Disc, pursuant to the terms of the Merger Agreement, and (ii) the change of control re at the 2022-12-28 meeting.
“Proposal No. 1. Approval of (i) the issuance of shares of common stock of the Company, which will represent more than 20% of the shares of the Company’s common stock outstanding immediately prior to the Merger, to stockholders of Disc, pursuant to the terms of the Merger Agreement, and (ii) the change of control resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively. This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain BROKER NON-VOTES 37,341,199 114,070 3,520 2,843,872”
Samuel Barone departed as Chief Medical Officer at Disc Medicine, Inc..
“Effective as of April 15, 2022 (the “Separation Date”), Samuel Barone, M.D. will depart as the Chief Medical Officer of Gemini Therapeutics, Inc.”
Georges Gemayel was appointed as Interim President and Chief Executive Officer at Disc Medicine, Inc..
“the Board appointed Dr. Georges Gemayel, the Company’s current Executive Chair, to serve as Interim President and Chief Executive Officer, effective as of February 28, 2022.”
Jason Meyenburg resigned as President and Chief Executive Officer at Disc Medicine, Inc..
“Mr. Meyenburg’s last date of employment with the Company as its President and Chief Executive Officer is February 28, 2022”
Georges Gemayel changed role as Executive Chair at Disc Medicine, Inc..
“Finally, Georges Gemayel, Ph.D., will transition to serve as the Executive Chair of the Company’s Board.”
Brian Piekos was appointed as Chief Business Officer at Disc Medicine, Inc..
“In addition, effective as of October 4, 2021, the Company has appointed Brian Piekos, the Company’s Chief Financial Officer, the additional title of Chief Business Officer, and Mr. Piekos has assumed additional leadership responsibilities for various functions including manufacturing, business development and investor relations.”
Samuel Barone changed role as Chief Medical Officer at Disc Medicine, Inc..
“On October 4, 2021, the Company’s Chief Medical Officer, Samuel Barone, M.D., entered into an agreement with the Company (the “Retention Agreement”) to modify his role and responsibilities.”
Scott Lauder resigned as Chief Technology Officer at Disc Medicine, Inc..
“On September 7, 2021, Dr. Scott Lauder, Ph.D. informed the Company of his intent to resign as Chief Technology Officer, effective as of September 17, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.